Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation.

Kovarik JJ, Kaltenecker CC, Kopecky C, Domenig O, Antlanger M, Werzowa J, Eskandary F, Kain R, Poglitsch M, Schmaldienst S, Böhmig GA, Säemann MD.

Sci Rep. 2019 Jul 5;9(1):9762. doi: 10.1038/s41598-019-46114-x.

2.

Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus.

Kopecky C, Lytvyn Y, Domenig O, Antlanger M, Kovarik JJ, Kaltenecker CC, Poglitsch M, Perkins BA, Rye KA, Cherney DZI, Säemann MD.

Diabetologia. 2019 Jun;62(6):1090-1093. doi: 10.1007/s00125-019-4871-8. Epub 2019 Apr 11. No abstract available.

PMID:
30976852
3.

Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.

Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A, Pacini G, Wrba T, Antlanger M, Schmaldienst S, Werzowa J, Säemann MD, Hecking M.

Am J Transplant. 2019 Mar;19(3):907-919. doi: 10.1111/ajt.15223. Epub 2019 Jan 25.

4.

Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping.

Antlanger M, Aschauer S, Kammerlander AA, Duca F, Säemann MD, Bonderman D, Mascherbauer J.

Sci Rep. 2018 Apr 3;8(1):5572. doi: 10.1038/s41598-018-23868-4.

5.

A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation.

Werzowa JM, Säemann MD, Mohl A, Bergmann M, Kaltenecker CC, Brozek W, Thomas A, Haidinger M, Antlanger M, Kovarik JJ, Kopecky C, Song PXK, Budde K, Pascual J, Hecking M.

PLoS One. 2018 Mar 8;13(3):e0193569. doi: 10.1371/journal.pone.0193569. eCollection 2018.

6.

Low- and High-renin Heart Failure Phenotypes with Clinical Implications.

Pavo N, Goliasch G, Wurm R, Novak J, Strunk G, Gyöngyösi M, Poglitsch M, Säemann MD, Hülsmann M.

Clin Chem. 2018 Mar;64(3):597-608. doi: 10.1373/clinchem.2017.278705. Epub 2017 Nov 14.

7.

Sports and HDL-Quality Reflected By Serum Amyloid A and Surfactant Protein B.

Sponder M, Kopecky C, Campean IA, Emich M, Fritzer-Szekeres M, Litschauer B, Graf S, Säemann MD, Strametz-Juranek J.

Int J Med Sci. 2017 Sep 3;14(11):1040-1048. doi: 10.7150/ijms.20388. eCollection 2017.

8.

Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis.

Kovarik JJ, Kernbauer E, Hölzl MA, Hofer J, Gualdoni GA, Schmetterer KG, Miftari F, Sobanov Y, Meshcheryakova A, Mechtcheriakova D, Witzeneder N, Greiner G, Ohradanova-Repic A, Waidhofer-Söllner P, Säemann MD, Decker T, Zlabinger GJ.

PLoS One. 2017 Jul 24;12(7):e0180900. doi: 10.1371/journal.pone.0180900. eCollection 2017.

9.

Blood volume-monitored regulation of ultrafiltration to decrease the dry weight in fluid-overloaded hemodialysis patients: a randomized controlled trial.

Antlanger M, Josten P, Kammer M, Exner I, Lorenz-Turnheim K, Eigner M, Paul G, Klauser-Braun R, Sunder-Plassmann G, Säemann MD, Hecking M.

BMC Nephrol. 2017 Jul 17;18(1):238. doi: 10.1186/s12882-017-0639-x.

10.

Pro- versus Anti-inflammatory Actions of HDLs in Innate Immunity.

Kopecky C, Michlits G, Säemann MD, Weichhart T.

Cell Metab. 2017 Jul 5;26(1):2-3. doi: 10.1016/j.cmet.2017.04.007. Epub 2017 Jun 22.

11.

Molecular remodeling of the renin-angiotensin system after kidney transplantation.

Antlanger M, Domenig O, Kovarik JJ, Kaltenecker CC, Kopecky C, Poglitsch M, Säemann MD.

J Renin Angiotensin Aldosterone Syst. 2017 Apr-Jun;18(2):1470320317705232. doi: 10.1177/1470320317705232.

12.

Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis.

Antlanger M, Aschauer S, Kopecky C, Hecking M, Kovarik JJ, Werzowa J, Mascherbauer J, Genser B, Säemann MD, Bonderman D.

Kidney Blood Press Res. 2017;42(1):165-176. doi: 10.1159/000473868. Epub 2017 Apr 11.

13.

Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease.

Antlanger M, Bernhofer S, Kovarik JJ, Kopecky C, Kaltenecker CC, Domenig O, Poglitsch M, Säemann MD.

Ann Med. 2017 Sep;49(6):525-533. doi: 10.1080/07853890.2017.1313447. Epub 2017 Apr 17.

PMID:
28358246
14.

Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction.

Pavo N, Wurm R, Goliasch G, Novak JF, Strunk G, Gyöngyösi M, Poglitsch M, Säemann MD, Hülsmann M.

J Am Coll Cardiol. 2016 Dec 27;68(25):2912-2914. doi: 10.1016/j.jacc.2016.10.017. No abstract available.

15.

Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.

Kovarik JJ, Kopecky C, Antlanger M, Domenig O, Kaltenecker CC, Werzowa J, Hecking M, Mahr S, Grömmer M, Wallner C, Aumayr K, Kain R, Zuckermann A, Poglitsch M, Säemann MD.

J Heart Lung Transplant. 2017 Mar;36(3):355-365. doi: 10.1016/j.healun.2016.08.022. Epub 2016 Sep 13.

PMID:
27773450
16.

Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney.

Domenig O, Manzel A, Grobe N, Königshausen E, Kaltenecker CC, Kovarik JJ, Stegbauer J, Gurley SB, van Oyen D, Antlanger M, Bader M, Motta-Santos D, Santos RA, Elased KM, Säemann MD, Linker RA, Poglitsch M.

Sci Rep. 2016 Sep 21;6:33678. doi: 10.1038/srep33678.

17.

HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.

Kopecky C, Ebtehaj S, Genser B, Drechsler C, Krane V, Antlanger M, Kovarik JJ, Kaltenecker CC, Parvizi M, Wanner C, Weichhart T, Säemann MD, Tietge UJ.

J Am Soc Nephrol. 2017 Mar;28(3):769-775. doi: 10.1681/ASN.2016030262. Epub 2016 Sep 9.

18.

Applied immuno-epidemiological research: an approach for integrating existing knowledge into the statistical analysis of multiple immune markers.

Genser B, Fischer JE, Figueiredo CA, Alcântara-Neves N, Barreto ML, Cooper PJ, Amorim LD, Saemann MD, Weichhart T, Rodrigues LC.

BMC Immunol. 2016 May 20;17(1):11. doi: 10.1186/s12865-016-0149-9.

19.

Molecular regulation of the renin-angiotensin system in haemodialysis patients.

Kovarik JJ, Antlanger M, Domenig O, Kaltenecker CC, Hecking M, Haidinger M, Werzowa J, Kopecky C, Säemann MD.

Nephrol Dial Transplant. 2016 May;31(5):851. doi: 10.1093/ndt/gfw071. Epub 2016 Mar 23. No abstract available.

PMID:
27190396
20.

When it rains, it pours: Peripartum cardiomyopathy with features of left-ventricular noncompaction in a hemodialysis patient.

Antlanger M, Kammerlander AA, Ullrich R, Haidinger M, Bonderman D, Mascherbauer J, Säemann MD.

Hemodial Int. 2016 Oct;20(4):E14-E17. doi: 10.1111/hdi.12427. Epub 2016 May 5.

PMID:
27147549
21.

[Diabetic kidney disease - Update 2016].

Sourij H, Edlinger R, Prischl F, Auinger M, Kautzky-Willer A, Säemann MD, Prager R, Clodi M, Schernthaner G, Mayer G, Oberbauer R, Rosenkranz AR.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S85-96. doi: 10.1007/s00508-016-0992-y. Review. German.

PMID:
27052231
22.

Assessment of beta-cell function and insulin secretion in subjects that underwent renal transplantation.

Tura A, Hecking M, Wolzt M, Saemann MD, Pacini G.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:2371-4. doi: 10.1109/EMBC.2015.7318870.

PMID:
26736770
23.

Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.

Werzowa J, Schwaiger B, Hecking M, Strassl R, Schmaldienst S, Böhmig GA, Genser B, Säemann MD.

Clin Transplant. 2015 Dec;29(12):1230-8. doi: 10.1111/ctr.12657. Epub 2015 Nov 25.

PMID:
26458731
24.

Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus.

Werzowa J, Pacini G, Hecking M, Fidler C, Haidinger M, Brath H, Thomas A, Säemann MD, Tura A.

J Diabetes Complications. 2015 Nov-Dec;29(8):1211-6. doi: 10.1016/j.jdiacomp.2015.07.014. Epub 2015 Jul 17.

PMID:
26264400
25.

Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk.

Zewinger S, Drechsler C, Kleber ME, Dressel A, Riffel J, Triem S, Lehmann M, Kopecky C, Säemann MD, Lepper PM, Silbernagel G, Scharnagl H, Ritsch A, Thorand B, de las Heras Gala T, Wagenpfeil S, Koenig W, Peters A, Laufs U, Wanner C, Fliser D, Speer T, März W.

Eur Heart J. 2015 Nov 14;36(43):3007-16. doi: 10.1093/eurheartj/ehv352. Epub 2015 Aug 6.

PMID:
26248570
26.

HDL cholesterol efflux capacity and cardiovascular events.

Kopecky C, Weichhart T, Säemann MD.

N Engl J Med. 2015 May 7;372(19):1869. doi: 10.1056/NEJMc1503139. No abstract available.

PMID:
25946299
27.

The diagnosis of posttransplantation diabetes mellitus: meeting the challenges.

Werzowa J, Hecking M, Haidinger M, Döller D, Sharif A, Tura A, Säemann MD.

Curr Diab Rep. 2015 May;15(5):27. doi: 10.1007/s11892-015-0601-x. Review.

PMID:
25777999
28.

Post-transplantation diabetes mellitus: evaluation of treatment strategies.

Haidinger M, Antlanger M, Kopecky C, Kovarik JJ, Säemann MD, Werzowa J.

Clin Transplant. 2015 May;29(5):415-24. doi: 10.1111/ctr.12541.

PMID:
25777150
29.

Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.

Kopecky C, Genser B, Drechsler C, Krane V, Kaltenecker CC, Hengstschläger M, März W, Wanner C, Säemann MD, Weichhart T.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):224-31. doi: 10.2215/CJN.06560714. Epub 2014 Nov 25.

30.

Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Hecking M, Bieber BA, Ethier J, Kautzky-Willer A, Sunder-Plassmann G, Säemann MD, Ramirez SP, Gillespie BW, Pisoni RL, Robinson BM, Port FK.

PLoS Med. 2014 Oct 28;11(10):e1001750. doi: 10.1371/journal.pmed.1001750. eCollection 2014 Oct.

31.

Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.

Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, Berlakovich G, Krebs M, Kautzky-Willer A, Schernthaner G, Marchetti P, Pacini G, Ojo A, Takahara S, Larsen JL, Budde K, Eller K, Pascual J, Jardine A, Bakker SJ, Valderhaug TG, Jenssen TG, Cohney S, Säemann MD.

Am J Transplant. 2014 Sep;14(9):1992-2000. doi: 10.1111/ajt.12850. Epub 2014 Aug 6.

32.

Molecular regulation of the renin-angiotensin system in haemodialysis patients.

Kovarik JJ, Antlanger M, Domenig O, Kaltenecker CC, Hecking M, Haidinger M, Werzowa J, Kopecky C, Säemann MD.

Nephrol Dial Transplant. 2015 Jan;30(1):115-23. doi: 10.1093/ndt/gfu265. Epub 2014 Aug 8. Erratum in: Nephrol Dial Transplant. 2016 May;31(5):851.

PMID:
25107336
33.

Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption.

Biesenbach P, Kain R, Derfler K, Perkmann T, Soleiman A, Benharkou A, Druml W, Rees A, Säemann MD.

PLoS One. 2014 Jul 31;9(7):e103568. doi: 10.1371/journal.pone.0103568. eCollection 2014.

34.

Restoration of renal function does not correct impairment of uremic HDL properties.

Kopecky C, Haidinger M, Birner-Grünberger R, Darnhofer B, Kaltenecker CC, Marsche G, Holzer M, Weichhart T, Antlanger M, Kovarik JJ, Werzowa J, Hecking M, Säemann MD.

J Am Soc Nephrol. 2015 Mar;26(3):565-75. doi: 10.1681/ASN.2013111219. Epub 2014 Jul 28.

35.

Addressing uncertainties in renal transplantation: hypomagnesemia and the case of diabetes prevention.

Werzowa JM, Säemann MD.

Transpl Int. 2014 Sep;27(9):892-4. doi: 10.1111/tri.12353. Review. No abstract available.

36.

Effect of different immunosuppressive drugs on immune cells from young and old healthy persons.

Welzl K, Kern G, Mayer G, Weinberger B, Säemann MD, Sturm G, Grubeck-Loebenstein B, Koppelstaetter C.

Gerontology. 2014;60(3):229-38. doi: 10.1159/000356020. Epub 2014 Jan 16.

37.

Fluid overload in hemodialysis patients: a cross-sectional study to determine its association with cardiac biomarkers and nutritional status.

Antlanger M, Hecking M, Haidinger M, Werzowa J, Kovarik JJ, Paul G, Eigner M, Bonderman D, Hörl WH, Säemann MD.

BMC Nephrol. 2013 Dec 2;14:266. doi: 10.1186/1471-2369-14-266.

38.

Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.

Haidinger M, Werzowa J, Hecking M, Antlanger M, Stemer G, Pleiner J, Kopecky C, Kovarik JJ, Döller D, Pacini G, Säemann MD.

Am J Transplant. 2014 Jan;14(1):115-23. doi: 10.1111/ajt.12518. Epub 2013 Nov 26.

39.

Comment on: Chakkera et al. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care 2013;36:1406-1412.

Hecking M, Sharif A, Port FK, Säemann MD.

Diabetes Care. 2013 Oct;36(10):e182. doi: 10.2337/dc13-1277. No abstract available.

40.

Significance of interdialytic weight gain versus chronic volume overload: consensus opinion.

Hecking M, Karaboyas A, Antlanger M, Saran R, Wizemann V, Chazot C, Rayner H, Hörl WH, Pisoni RL, Robinson BM, Sunder-Plassmann G, Moissl U, Kotanko P, Levin NW, Säemann MD, Kalantar-Zadeh K, Port FK, Wabel P.

Am J Nephrol. 2013;38(1):78-90. doi: 10.1159/000353104. Epub 2013 Jul 6.

41.

Glucose metabolism after renal transplantation.

Hecking M, Kainz A, Werzowa J, Haidinger M, Döller D, Tura A, Karaboyas A, Hörl WH, Wolzt M, Sharif A, Roden M, Moro E, Pacini G, Port FK, Säemann MD.

Diabetes Care. 2013 Sep;36(9):2763-71. doi: 10.2337/dc12-2441. Epub 2013 May 8.

42.

Hereditary amyloidosis caused by R554L fibrinogen Aα-chain mutation in a Spanish family and review of the literature.

Haidinger M, Werzowa J, Kain R, Antlanger M, Hecking M, Pfaffenberger S, Mascherbauer J, Gremmel T, Gilbertson JA, Rowczenio D, Weichhart T, Kopecky C, Hörl WH, Hawkins PN, Säemann MD.

Amyloid. 2013 Jun;20(2):72-9. doi: 10.3109/13506129.2013.781998. Epub 2013 Apr 3.

PMID:
23551149
43.

Eicosanoid modulation by the short-chain fatty acid n-butyrate in human monocytes.

Kovarik JJ, Hölzl MA, Hofer J, Waidhofer-Söllner P, Sobanov Y, Koeffel R, Saemann MD, Mechtcheriakova D, Zlabinger GJ.

Immunology. 2013 Jul;139(3):395-405. doi: 10.1111/imm.12089.

44.

Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial.

Werzowa J, Hecking M, Haidinger M, Lechner F, Döller D, Pacini G, Stemer G, Pleiner J, Frantal S, Säemann MD.

Transplantation. 2013 Feb 15;95(3):456-62. doi: 10.1097/TP.0b013e318276a20e.

PMID:
23380864
45.

Novel views on new-onset diabetes after transplantation: development, prevention and treatment.

Hecking M, Werzowa J, Haidinger M, Hörl WH, Pascual J, Budde K, Luan FL, Ojo A, de Vries AP, Porrini E, Pacini G, Port FK, Sharif A, Säemann MD; European-New-Onset Diabetes After Transplantation Working Group.

Nephrol Dial Transplant. 2013 Mar;28(3):550-66. doi: 10.1093/ndt/gfs583. Epub 2013 Jan 17.

46.

p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin.

Katholnig K, Kaltenecker CC, Hayakawa H, Rosner M, Lassnig C, Zlabinger GJ, Gaestel M, Müller M, Hengstschläger M, Hörl WH, Park JM, Säemann MD, Weichhart T.

J Immunol. 2013 Feb 15;190(4):1519-27. doi: 10.4049/jimmunol.1202683. Epub 2013 Jan 11.

47.

Inflammation alters HDL composition and function: implications for HDL-raising therapies.

Marsche G, Saemann MD, Heinemann A, Holzer M.

Pharmacol Ther. 2013 Mar;137(3):341-51. doi: 10.1016/j.pharmthera.2012.12.001. Epub 2012 Dec 14. Review.

PMID:
23246719
48.

Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.

Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Säemann MD, Mueller NJ, Merville P, Emery V, Nashan B.

Rev Med Virol. 2013 Mar;23(2):97-125. doi: 10.1002/rmv.1733. Epub 2012 Nov 20. Review.

PMID:
23165654
49.

Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.

Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.

Transplantation. 2012 Jun 15;93(11):1075-85. doi: 10.1097/TP.0b013e31824810e6. Review.

PMID:
22683823
50.

Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial.

Hecking M, Antlanger M, Winnicki W, Reiter T, Werzowa J, Haidinger M, Weichhart T, Polaschegg HD, Josten P, Exner I, Lorenz-Turnheim K, Eigner M, Paul G, Klauser-Braun R, Hörl WH, Sunder-Plassmann G, Säemann MD.

Trials. 2012 Jun 8;13:79. doi: 10.1186/1745-6215-13-79.

Supplemental Content

Loading ...
Support Center